Health-care companies rose after strong earnings from one fast-growing company.
Novo Nordisk shares rose after the Danish obesity-drug maker's first-quarter earnings topped Wall Street expectations. As widely anticipated, the drug maker reduced its growth forecast to reflect the appearance of copycat versions of its blockbuster weight-loss and diabetes drugs in the U.S.
Hims & Hers, the online pharmacy that recently struck a distribution deal with Novo Nordisk, saw shares rise.
If President Trump imposes drug tariffs that affect the cheap generic medicines Teva Pharmaceutical Industries makes, the company's chief executive says he'll have no choice but to raise their prices.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
May 07, 2025 17:32 ET (21:32 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。